Allan Pereira, MD, PhD

Dr. Kim reviews the primary results of HERIZON-GEA-01. Both zanidatamab-containing arms significantly improved progression-free survival vs trastuzumab plus chemotherapy, with a similar magnitude of benefit.

Allan Lima Pereira, MD, of Moffitt Cancer Center, and Sunnie Kim, MD, of University of Colorado Cancer Center, open their discussion by reviewing how first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA) has evolved.